Castle Biosciences, Inc. 2024 Annual Meeting of Stockholders Proxy Statement

Ticker: CSTL · Form: DEF 14A · Filed: 2024-04-10T00:00:00.000Z

Sentiment: neutral

Topics: Proxy Statement, Annual Meeting, Stockholders, Voting, Castle Biosciences

TL;DR

<b>Castle Biosciences, Inc. has filed its Definitive Proxy Statement for the 2024 Annual Meeting of Stockholders, scheduled for May 23, 2024, encouraging early voting.</b>

AI Summary

CASTLE BIOSCIENCES INC (CSTL) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. Castle Biosciences, Inc. will hold its 2024 Annual Meeting of Stockholders on May 23, 2024, at 10:00 a.m. central time. The company is providing a Proxy Statement and 2023 Annual Report to guide stockholders on the meeting's business. Stockholders are encouraged to submit their votes early. The filing is a Definitive Proxy Statement (DEF 14A) filed on April 10, 2024. The company's principal executive offices are located at 505 S FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD, TX 77546.

Why It Matters

For investors and stakeholders tracking CASTLE BIOSCIENCES INC, this filing contains several important signals. This filing provides essential information for stockholders to understand the proposals and exercise their voting rights at the upcoming annual meeting. The early encouragement to vote suggests the company is seeking to ensure high participation and clear outcomes for the matters presented.

Risk Assessment

Risk Level: low — CASTLE BIOSCIENCES INC shows low risk based on this filing. The filing is a routine proxy statement, providing information for an upcoming shareholder meeting with no immediate financial or operational disclosures that would indicate high risk.

Analyst Insight

Stockholders should review the proxy statement to understand the proposals and vote accordingly, paying attention to any executive compensation or board nominations.

Key Numbers

Key Players & Entities

FAQ

When did CASTLE BIOSCIENCES INC file this DEF 14A?

CASTLE BIOSCIENCES INC filed this Proxy Statement (DEF 14A) with the SEC on April 10, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by CASTLE BIOSCIENCES INC (CSTL).

Where can I read the original DEF 14A filing from CASTLE BIOSCIENCES INC?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by CASTLE BIOSCIENCES INC.

What are the key takeaways from CASTLE BIOSCIENCES INC's DEF 14A?

CASTLE BIOSCIENCES INC filed this DEF 14A on April 10, 2024. Key takeaways: Castle Biosciences, Inc. will hold its 2024 Annual Meeting of Stockholders on May 23, 2024, at 10:00 a.m. central time.. The company is providing a Proxy Statement and 2023 Annual Report to guide stockholders on the meeting's business.. Stockholders are encouraged to submit their votes early..

Is CASTLE BIOSCIENCES INC a risky investment based on this filing?

Based on this DEF 14A, CASTLE BIOSCIENCES INC presents a relatively low-risk profile. The filing is a routine proxy statement, providing information for an upcoming shareholder meeting with no immediate financial or operational disclosures that would indicate high risk.

What should investors do after reading CASTLE BIOSCIENCES INC's DEF 14A?

Stockholders should review the proxy statement to understand the proposals and vote accordingly, paying attention to any executive compensation or board nominations. The overall sentiment from this filing is neutral.

How does CASTLE BIOSCIENCES INC compare to its industry peers?

Castle Biosciences, Inc. operates in the medical laboratories sector, providing diagnostic tests.

Are there regulatory concerns for CASTLE BIOSCIENCES INC?

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.

Industry Context

Castle Biosciences, Inc. operates in the medical laboratories sector, providing diagnostic tests.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.

What Investors Should Do

  1. Review the proxy statement for details on proposals and director nominations.
  2. Submit your vote by the deadline to ensure your voice is heard.
  3. Attend the virtual annual meeting on May 23, 2024, if possible.

Key Dates

Year-Over-Year Comparison

This is the initial filing of the 2024 proxy statement, providing information for the upcoming annual meeting.

Filing Stats: 4,331 words · 17 min read · ~14 pages · Grade level 15.9 · Accepted 2024-04-10 16:05:57

Key Financial Figures

Filing Documents

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 38

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 38 EXECUTIVE OFFICERS 41 COMPENSATION DISCUSSION AND ANALYSIS 42 Named Executive Officers 42 Business Overview 42

Executive Compensation Philosophy and Objectives 43

Executive Compensation Philosophy and Objectives 43 Summary of our Executive Compensation Program 44 2023 Stockholder Outreach 45 Stockholder Feedback and Board Responsiveness 46 Compensation Committee Oversight of Compensation-Related Risks 47 Compensation Determination Process 49 Elements of Our Executive Compensation Program 52 Agreements with our NEOs 57 Potential Benefits upon Termination or Change-in-Control 58 Pension Benefits and Nonqualified Deferred Compensation 59 Other Compensation Practices and Policies 60 Compensation Committee Report 63

EXECUTIVE COMPENSATION TABLES 64

EXECUTIVE COMPENSATION TABLES 64 Summary Compensation Table 64 Grants of Plan-Based Awards 65 Outstanding Equity Awards at Fiscal Year-End 66 Option Exercises and Stock Vested in 2023 68 Potential payments Upon Termination or Change-in-Control 68 CEO PAY RATIO 70 PAY VERSUS PERFORMANCE 71 DELINQUENT SECTION 16(a) REPORTS 75 EQUITY COMPENSATION PLAN INFORMATION 76 TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATIONS 81 HOUSEHOLDING OF PROXY MATERIALS 84 ANNUAL REPORT ON FORM 10-K 85 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING 86 OTHER MATTERS 92 v Castle Biosciences 2024 Proxy Statement Table of Contents Proxy Summary VOTING MATTERS Please read this Proxy Statement for the 2024 annual meeting of stockholders (including any adjournments, continuations or postponements thereof) of Castle Biosciences, Inc., a Delaware corporation and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 before voting on the following matters: $220M in revenue 60% year-over-year growth Proposals Board Vote Recommendation Page Reference (for more detail) 1 Election of Two Class II Directors FOR each nominee 9 70,429 delivered test reports 59% year-over-year growth 2 Ratification of Independent Auditor FOR 34 3 Advisory Approval of Executive Compensation (Say-on-Pay) FOR 37 HOW TO VOTE By Internet (www.proxyvote.com) By Phone (1-800-690-6903) By Mail (Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717) $243M in cash, cash equivalents and marketable investment securities as of December 31, 2023 See this Proxy Statement for directions on voting by proxy and to see how your votes are counted. BUSINESS OVERVIEW Our commercially available proprietary tests focus on answering clinical questions arising during the treatment of: Dermatologic cancers — DecisionDx-Melanoma, DecisionDx-SCC, and MyPath Melanoma Barrett's esophagus — TissueCypher Barrett's Esophagus T

Executive compensation

Executive compensation Greenhouse Gas Emissions and other Environmental Disclosures Board diversity Enhancement to proxy disclosures Board structure Gender Pay Analysis After considering stockholder feedback gathered in the fall of 2022 and 2023, as well as input from management and based in part on the Compensation Committee's independent compensation consultant, the Compensation Committee approved significant changes to our executive compensation program that were implemented in late 2022, in 2023 and early 2024. These changes included: Continuing to expand our executive compensation disclosure in our proxy statement beyond the scaled disclosure required of smaller reporting companies to respond to shareholder feedback and better describe the committee process and policy structure; Disclosing the material principles underlying Castle's executive compensation policies and decisions and the most important factors relevant to changes we have made to better align our policies with investor feedback, ongoing trends and good governance practices such as: The introduction of performance-based equity incentive awards in the compensation package in 2022 for our executive officers with the grants to our CEO including 50% performance-based equity; Adoption of an Incentive Compensation Recovery Policy ("Clawback Policy"); Adoption of stock ownership guidelines for our directors and executive officers; Adoption of a policy on director time commitment; and Shifting of our annual grant cycle from the fourth quarter of the fiscal year to the first quarter of the subsequent year to (i) align with our final Board-approved budget, our fiscal year performance period, our goal setting and the reporting of our financial results and (ii) align with our commitment to performance-based equity as noted above. Each of the above are outlined in more detail in this Proxy Statement. The Compensation Committee will continue to consider stockholder feedback and the outcomes of fu

View on Read The Filing